Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2025-12-29 00:00:00 ET · period of report 2025-12-22 · accession 0001601830-25-000176 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2025-12-22 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | S - Sale | $4.41 | -124.4K | 611.1K | -17% | -$548.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-12-22 | S | D | 124,403 | $4.41 | 611,135 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $4.30 to $4.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |